Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 3 | 2023 | 45 | 1.640 |
Why?
|
| Diabetic Retinopathy | 2 | 2023 | 108 | 1.340 |
Why?
|
| HSP90 Heat-Shock Proteins | 7 | 2018 | 61 | 1.250 |
Why?
|
| PPAR alpha | 2 | 2020 | 32 | 1.240 |
Why?
|
| Drug Design | 6 | 2020 | 62 | 1.160 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2022 | 152 | 0.890 |
Why?
|
| Oxazolidinones | 1 | 2022 | 4 | 0.810 |
Why?
|
| Vascular Diseases | 2 | 2020 | 67 | 0.800 |
Why?
|
| Macular Degeneration | 1 | 2023 | 79 | 0.790 |
Why?
|
| Spores, Bacterial | 1 | 2021 | 45 | 0.740 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2020 | 4 | 0.720 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 660 | 0.710 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 213 | 0.700 |
Why?
|
| Benzylamines | 1 | 2020 | 19 | 0.680 |
Why?
|
| Structure-Activity Relationship | 6 | 2020 | 204 | 0.650 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 129 | 0.640 |
Why?
|
| Carbazoles | 1 | 2019 | 5 | 0.640 |
Why?
|
| Depsipeptides | 1 | 2018 | 5 | 0.620 |
Why?
|
| Endopeptidase Clp | 1 | 2018 | 9 | 0.620 |
Why?
|
| Bacterial Proteins | 2 | 2022 | 474 | 0.610 |
Why?
|
| Quinolines | 1 | 2018 | 25 | 0.580 |
Why?
|
| Triazines | 2 | 2014 | 11 | 0.560 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2018 | 43 | 0.520 |
Why?
|
| Indolizines | 1 | 2016 | 1 | 0.520 |
Why?
|
| Spiro Compounds | 1 | 2016 | 5 | 0.510 |
Why?
|
| Endopeptidases | 1 | 2016 | 20 | 0.510 |
Why?
|
| Models, Molecular | 5 | 2020 | 445 | 0.490 |
Why?
|
| Molecular Structure | 6 | 2018 | 240 | 0.490 |
Why?
|
| Biological Products | 1 | 2016 | 60 | 0.480 |
Why?
|
| Amidines | 1 | 2014 | 8 | 0.440 |
Why?
|
| Bleomycin | 1 | 2014 | 11 | 0.440 |
Why?
|
| Dipeptides | 1 | 2014 | 22 | 0.440 |
Why?
|
| Membrane Proteins | 2 | 2018 | 469 | 0.410 |
Why?
|
| Pyrimidines | 1 | 2014 | 121 | 0.410 |
Why?
|
| Gram-Negative Bacteria | 2 | 2022 | 58 | 0.380 |
Why?
|
| Humans | 17 | 2023 | 27169 | 0.360 |
Why?
|
| Drug Discovery | 2 | 2020 | 32 | 0.340 |
Why?
|
| Macrolides | 2 | 2009 | 19 | 0.340 |
Why?
|
| Virulence | 2 | 2021 | 144 | 0.330 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 143 | 0.330 |
Why?
|
| Amides | 1 | 2009 | 18 | 0.320 |
Why?
|
| Protein Conformation | 4 | 2016 | 253 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 498 | 0.310 |
Why?
|
| Ligands | 2 | 2020 | 170 | 0.310 |
Why?
|
| Drug Resistance | 1 | 2009 | 42 | 0.310 |
Why?
|
| Proteolysis | 3 | 2018 | 55 | 0.310 |
Why?
|
| Animals | 8 | 2022 | 10093 | 0.300 |
Why?
|
| Oxidative Stress | 1 | 2010 | 635 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 135 | 0.240 |
Why?
|
| Cell Line | 2 | 2020 | 683 | 0.230 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 2 | 2016 | 4 | 0.230 |
Why?
|
| Cytoskeletal Proteins | 2 | 2016 | 42 | 0.230 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 77 | 0.220 |
Why?
|
| Glycoproteins | 2 | 2016 | 120 | 0.220 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 7 | 0.210 |
Why?
|
| Linezolid | 1 | 2022 | 4 | 0.200 |
Why?
|
| Eye Proteins | 2 | 2016 | 197 | 0.200 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2022 | 5 | 0.190 |
Why?
|
| Bortezomib | 1 | 2021 | 18 | 0.190 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 45 | 0.190 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 39 | 0.190 |
Why?
|
| Gene Editing | 1 | 2021 | 19 | 0.190 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 62 | 0.190 |
Why?
|
| Protein Isoforms | 1 | 2021 | 118 | 0.190 |
Why?
|
| Benzoquinones | 3 | 2009 | 26 | 0.180 |
Why?
|
| Lactams, Macrocyclic | 3 | 2009 | 26 | 0.180 |
Why?
|
| Clostridium Infections | 1 | 2021 | 66 | 0.180 |
Why?
|
| Escherichia coli Proteins | 1 | 2022 | 113 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 73 | 0.170 |
Why?
|
| Streptozocin | 1 | 2020 | 11 | 0.170 |
Why?
|
| Capillary Permeability | 1 | 2020 | 38 | 0.170 |
Why?
|
| Escherichia coli | 1 | 2022 | 330 | 0.170 |
Why?
|
| Mutation | 2 | 2021 | 820 | 0.160 |
Why?
|
| Prospective Studies | 1 | 2023 | 1221 | 0.160 |
Why?
|
| Phenotype | 1 | 2021 | 668 | 0.160 |
Why?
|
| Inflammation | 1 | 2023 | 608 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2018 | 130 | 0.150 |
Why?
|
| Isoenzymes | 1 | 2018 | 86 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1406 | 0.150 |
Why?
|
| Eye Diseases | 1 | 2018 | 31 | 0.140 |
Why?
|
| Cycloaddition Reaction | 2 | 2014 | 3 | 0.140 |
Why?
|
| Biomarkers | 1 | 2020 | 738 | 0.140 |
Why?
|
| Proteomics | 1 | 2018 | 177 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 590 | 0.130 |
Why?
|
| Rats | 1 | 2020 | 1554 | 0.130 |
Why?
|
| Acetanilides | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hydroxybenzoates | 1 | 2016 | 6 | 0.130 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 18 | 0.130 |
Why?
|
| Benzoates | 1 | 2016 | 30 | 0.130 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 55 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 60 | 0.130 |
Why?
|
| Catalysis | 1 | 2016 | 133 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2016 | 176 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 70 | 0.120 |
Why?
|
| Mice | 3 | 2022 | 4478 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2018 | 116 | 0.110 |
Why?
|
| Stereoisomerism | 2 | 2014 | 45 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 18 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2011 | 102 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 98 | 0.100 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 22 | 0.100 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2012 | 19 | 0.100 |
Why?
|
| Drosophila | 1 | 2012 | 32 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 22 | 0.100 |
Why?
|
| Autophagy | 1 | 2012 | 72 | 0.100 |
Why?
|
| Protein Transport | 1 | 2012 | 153 | 0.090 |
Why?
|
| Novobiocin | 1 | 2011 | 14 | 0.090 |
Why?
|
| DNA | 1 | 2013 | 365 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 448 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2009 | 21 | 0.080 |
Why?
|
| Benzene Derivatives | 1 | 2009 | 7 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 163 | 0.080 |
Why?
|
| Protein Binding | 3 | 2018 | 637 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2009 | 58 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 49 | 0.080 |
Why?
|
| Crystallography, X-Ray | 2 | 2018 | 218 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2016 | 775 | 0.060 |
Why?
|
| Binding Sites | 2 | 2016 | 342 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 1271 | 0.050 |
Why?
|
| Female | 3 | 2022 | 14662 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2016 | 506 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 59 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2022 | 45 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 48 | 0.050 |
Why?
|
| Salmonella typhimurium | 1 | 2022 | 68 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2022 | 147 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2022 | 236 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2018 | 66 | 0.040 |
Why?
|
| Dogs | 1 | 2018 | 506 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 32 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 102 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 68 | 0.030 |
Why?
|
| Glaucoma | 1 | 2016 | 52 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 113 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 353 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 34 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2013 | 44 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 73 | 0.030 |
Why?
|
| Pyrroles | 1 | 2013 | 35 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 71 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 179 | 0.030 |
Why?
|
| Male | 1 | 2022 | 13040 | 0.020 |
Why?
|